Biosense Webster, Inc. Completes Enrollment in Ground-Breaking SMART-AF Trial

Published: Jan 12, 2012

DIAMOND BAR, Calif.--(BUSINESS WIRE)--Biosense Webster Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the completion of enrollment in their latest ground-breaking clinical trial, the SMART-AF Investigational Device Exemption (IDE) study.

Back to news